Experience of using certain immunocytochemical markers in preoperative prognostication of aggressiveness in highly differentiated thyroid tumors
Open Access
- 30 June 2025
- journal article
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 37-41
Abstract
Objective — to improve treatment outcomes for patients with highly differentiated papillary thyroid microcarcinoma (PTMC) by developing a differentiated surgical approach based on the preoperative assessment of cytokeratin-17 (CK17) and thyroid peroxidase (TPO) expression levels in fine-needle aspiration (FNA) samples of the thyroid gland. Materials and methods. The study included 31 patients with cytologically confirmed PTMC (≤ 10 mm) without signs of autoimmune thyroiditis or metastases. All patients underwent immunocytochemical analysis of thyroid FNA samples to evaluate CK17 and TPO expression levels. Based on the results, patients were stratified into two groups: those with an aggressive tumor phenotype (CK17 ≥ 10%, TPO <25%) and those with a non-aggressive phenotype. Accordingly, patients underwent either total thyroidectomy with lymph node dissection or hemithyroidectomy. Results. In 7 (22.6%) patients, an aggressive immunocytochemical profile was established, which correlated with the detection of follicular-infiltrative or diffuse sclerotic variant of MVP according to histological analysis. The remaining patients were diagnosed with non-aggressive morphological variants (classical, varicose). No recurrence or progression of the disease was recorded during follow-up. A statistically significant (p<0.05) association between high expression of CK-17, decreased TPO levels and aggressive course of MVP was established. Conclusions. Immunocytochemical assessment of the expression of CC-17 and TPO is informative for stratifying the risk of MVP aggressiveness at the preoperative stage. The use of these markers makes it possible to individualise the scope of surgical intervention in accordance with the biological behaviour of the tumour, which is consistent with current recommendations (ATA 2023, NCCN 2024, WHO 2022).Keywords
This publication has 7 references indexed in Scilit:
- Цитологічне прогнозування агресії раку щитоподібної залози як новий перспективний напрямок у клінічній тиреоїдологіїEndokrynologia, 2024
- High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networksCell Death Discovery, 2024
- ЦИТОКЕРАТИН 17 І ТИРЕОЇДНА ПЕРОКСИДАЗА В ЯКОСТІ ІМУНОЦИТОХІМІЧНИХ МАРКЕРІВ ДООПЕРАЦІЙНОГО ПРОГНОЗУВАННЯ РАДІОЙОДРЕЗИСТЕНТНОСТІ ТА ЕФЕКТИВНОСТІ РАДІОЙОДТЕРАПІЇ ПАПІЛЯРНОГО РАКУ ЩИТОПОДІБНОЇ ЗАЛОЗИOncology, 2019
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- The value of thyroperoxidase as a prognostic factor for differentiated thyroid cancer -- a long-term follow-up studyThyroid Research, 2015
- Tall Cell Variant of Papillary Thyroid Carcinoma: A Population-Based Study in IcelandThyroid®, 2015
- Low risk papillary thyroid cancerBMJ, 2014